RNAi biotech Alnylam Pharmaceuticals is planning to spend $200 million on a manufacturing plant in a bet that its pipeline therapies will find their way to market in the coming years.
In a sign of the continuing headwinds for biotech, Shield Therapeutics has had to cut both its price and its original aims to see through its U.K. IPO.
Actelion, the standard bearer in treatments for pulmonary arterial hypertension, is scouting for new disease areas as it rolls out its next potential blockbuster, hoping to keep up its pace of growth by pivoting away from its home base.
The FDA has slapped a partial clinical hold on CTI BioPharma's late-stage myelofibrosis drug pacritinib after patients in the drug arm of a Phase III study began to die at a higher rate than those in the placebo group. The drug arm also registered a higher number of adverse events, further raising concerns about the safety of the drug.
Bothell, WA-based biotech OncoGenex is laying off nearly a third of its workforce to conserve cash as it holds out hope for its lead cancer program in a move designed to keep the doors open until Phase III results come in.
After more than 60 days without a single successful biotech IPO, a pair of drug developers have made their way to the Nasdaq, going public without offering discounts and heralding hope that a dismal market might pick back up.
Cambridge, U.K.'s Mission Therapeutics raised £60 million ($86 million) in equity to fund its work in a novel biological pathway, uniting high-profile investors Imperial Innovations and Woodford Patient Capital Trust in the round.
Canada's Transition Therapeutics is touting positive Phase II data for a once-a-week GLP-1 treatment, triggering a decision point for partner Eli Lilly, which bought into the program in a $247 million deal.
The star of Allergan's pipeline, a ketamine-like drug for depression, secured the FDA's coveted breakthrough therapy designation, guaranteeing the company access to top agency officials as it moves toward late-stage development.
Merck is nearing FDA approval for its Clostridium difficile-fighting antibody, picking up the agency's priority review designation with the promise of a shortened vetting process.